Integer Holdings Co. (NYSE:ITGR) Receives Average Recommendation of “Moderate Buy” from Analysts

Integer Holdings Co. (NYSE:ITGR) has received a consensus recommendation of “Moderate Buy” from the six research firms that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $120.50.

A number of equities analysts recently issued reports on the stock. CL King started coverage on shares of Integer in a research report on Thursday, March 14th. They issued a “buy” rating and a $137.00 target price for the company. KeyCorp raised their price objective on shares of Integer from $123.00 to $139.00 and gave the company an “overweight” rating in a research note on Tuesday, April 9th. Bank of America raised Integer from a “neutral” rating to a “buy” rating and increased their price target for the company from $105.00 to $135.00 in a research note on Monday, April 15th. Finally, Benchmark boosted their price objective on Integer from $105.00 to $130.00 and gave the stock a “buy” rating in a research note on Thursday, March 28th.

Institutional Investors Weigh In On Integer

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Blue Trust Inc. raised its holdings in Integer by 483.3% during the 4th quarter. Blue Trust Inc. now owns 455 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 377 shares during the period. Principal Securities Inc. purchased a new stake in shares of Integer in the 4th quarter valued at approximately $67,000. Emerald Mutual Fund Advisers Trust boosted its stake in Integer by 66.6% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 1,461 shares of the medical equipment provider’s stock worth $115,000 after purchasing an additional 584 shares during the period. Van ECK Associates Corp grew its position in Integer by 22.0% during the 3rd quarter. Van ECK Associates Corp now owns 1,733 shares of the medical equipment provider’s stock worth $136,000 after purchasing an additional 313 shares in the last quarter. Finally, Quadrant Capital Group LLC grew its position in Integer by 10.2% during the 4th quarter. Quadrant Capital Group LLC now owns 1,427 shares of the medical equipment provider’s stock worth $141,000 after purchasing an additional 132 shares in the last quarter. 99.29% of the stock is owned by institutional investors and hedge funds.

Integer Stock Performance

ITGR stock opened at $111.25 on Friday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.71 and a current ratio of 2.80. Integer has a 1 year low of $69.40 and a 1 year high of $123.99. The stock’s fifty day moving average is $112.91 and its two-hundred day moving average is $99.57. The stock has a market capitalization of $3.73 billion, a price-to-earnings ratio of 41.36, a PEG ratio of 1.63 and a beta of 1.10.

Integer (NYSE:ITGR) last announced its quarterly earnings results on Thursday, February 15th. The medical equipment provider reported $1.39 EPS for the quarter, beating the consensus estimate of $1.34 by $0.05. The company had revenue of $413.15 million for the quarter, compared to analyst estimates of $409.04 million. Integer had a net margin of 5.68% and a return on equity of 10.80%. Integer’s revenue was up 10.9% compared to the same quarter last year. During the same quarter last year, the business earned $1.11 earnings per share. On average, research analysts predict that Integer will post 5.31 EPS for the current year.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.